These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 38504678)
41. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. ; Thompson MG; Yoon SK; Naleway AL; Meece J; Fabrizio TP; Caban-Martinez AJ; Burgess JL; Gaglani M; Olsho LEW; Bateman A; Lundgren J; Grant L; Phillips AL; Groom HC; Stefanski E; Solle NS; Ellingson K; Lutrick K; Dunnigan K; Wesley MG; Guenther K; Hunt A; Mak J; Hegmann KT; Kuntz JL; Bissonnette A; Hollister J; Rose S; Morrill TC; Respet K; Fowlkes AL; Thiese MS; Rivers P; Herring MK; Odean MJ; Yoo YM; Brunner M; Bedrick EJ; Fleary DE; Jones JT; Praggastis J; Romine J; Dickerson M; Khan SM; Lamberte JM; Beitel S; Webby RJ; Tyner HL JAMA; 2022 Oct; 328(15):1523-1533. PubMed ID: 36255426 [TBL] [Abstract][Full Text] [Related]
42. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry. Cortellini A; Tabernero J; Mukherjee U; Salazar R; Sureda A; Maluquer C; Ferrante D; Bower M; Sharkey R; Mirallas O; Plaja A; Cucurull M; Mesia R; Dalla Pria A; Newsom-Davis T; Van Hemelrijck M; Sita-Lumsden A; Apthorp E; Vincenzi B; Di Fazio GR; Tonini G; Pantano F; Bertuzzi A; Rossi S; Brunet J; Lambertini M; Pedrazzoli P; Biello F; D'Avanzo F; Lee AJX; Shawe-Taylor M; Rogers L; Murphy C; Cooper L; Andaleeb R; Khalique S; Bawany S; Ahmed S; Carmona-García MC; Fort-Culillas R; Liñan R; Zoratto F; Rizzo G; Perachino M; Doonga K; Gaidano G; Bruna R; Patriarca A; Martinez-Vila C; Pérez Criado I; Giusti R; Mazzoni F; Antonuzzo L; Santoro A; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Diamantis N; Bertulli R; Fulgenzi CAM; D'Alessio A; Ruiz-Camps I; Saoudi-Gonzalez N; Garcia Illescas D; Medina I; Fox L; Gennari A; Aguilar-Company J; Pinato DJ; Lancet Oncol; 2023 Apr; 24(4):335-346. PubMed ID: 36898391 [TBL] [Abstract][Full Text] [Related]
43. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551 [TBL] [Abstract][Full Text] [Related]
44. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Pinato DJ; Aguilar-Company J; Ferrante D; Hanbury G; Bower M; Salazar R; Mirallas O; Sureda A; Plaja A; Cucurull M; Mesia R; Townsend S; Jackson A; Dalla Pria A; Newsom-Davis T; Handford J; Sita-Lumsden A; Apthorp E; Vincenzi B; Bertuzzi A; Brunet J; Lambertini M; Maluquer C; Pedrazzoli P; Biello F; Sinclair A; Bawany S; Khalique S; Rossi S; Rogers L; Murphy C; Belessiotis K; Carmona-García MC; Sharkey R; García-Illescas D; Rizzo G; Perachino M; Saoudi-Gonzalez N; Doonga K; Fox L; Roldán E; Gaidano G; Ruiz-Camps I; Bruna R; Patriarca A; Martinez-Vila C; Cantini L; Zambelli A; Giusti R; Mazzoni F; Caliman E; Santoro A; Grosso F; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Prat A; Tucci M; Libertini M; Grisanti S; Mukherjee U; Diamantis N; Fusco V; Generali D; Provenzano S; Gennari A; Tabernero J; Cortellini A; Lancet Oncol; 2022 Jul; 23(7):865-875. PubMed ID: 35660139 [TBL] [Abstract][Full Text] [Related]
45. The Omicron Variant Is Associated with a Reduced Risk of the Post COVID-19 Condition and Its Main Phenotypes Compared to the Wild-Type Virus: Results from the EuCARE-POSTCOVID-19 Study. Bai F; Santoro A; Hedberg P; Tavelli A; De Benedittis S; de Morais Caporali JF; Marinho CC; Leite AS; Santoro MM; Ceccherini Silberstein F; Iannetta M; Juozapaité D; Strumiliene E; Almeida A; Toscano C; Ruiz-Quiñones JA; Mommo C; Fanti I; Incardona F; Cozzi-Lepri A; Marchetti G; Viruses; 2024 Sep; 16(9):. PubMed ID: 39339976 [TBL] [Abstract][Full Text] [Related]
46. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. Veneti L; Berild JD; Watle SV; Starrfelt J; Greve-Isdahl M; Langlete P; Bøås H; Bragstad K; Hungnes O; Meijerink H Int J Infect Dis; 2023 May; 130():182-188. PubMed ID: 36893942 [TBL] [Abstract][Full Text] [Related]
47. Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China. Sha J; Meng C; Sun J; Sun L; Gu R; Liu J; Zhu X; Zhu D J Infect Public Health; 2023 Mar; 16(3):422-429. PubMed ID: 36731245 [TBL] [Abstract][Full Text] [Related]
48. General practitioner visits after SARS-CoV-2 omicron compared with the delta variant in children in Norway: a prospective nationwide registry study. Arntzen SS; Gjefsen HM; Telle KE; Magnusson K; Størdal K; Håberg SE; Kinge JM BMJ Paediatr Open; 2022 Aug; 6(1):. PubMed ID: 36053662 [TBL] [Abstract][Full Text] [Related]
49. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Alkodaymi MS; Omrani OA; Fawzy NA; Shaar BA; Almamlouk R; Riaz M; Obeidat M; Obeidat Y; Gerberi D; Taha RM; Kashour Z; Kashour T; Berbari EF; Alkattan K; Tleyjeh IM Clin Microbiol Infect; 2022 May; 28(5):657-666. PubMed ID: 35124265 [TBL] [Abstract][Full Text] [Related]
50. The Burden and Characteristics of Post-COVID-19 Conditions Among Laboratory-Confirmed Delta and Omicron COVID-19 Cases: A Preliminary Study From Maharashtra, India. Karyakarte RP; Das R; Rajmane MV; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Kulkarni PP; Nizarudeen S; Mukade S; Joshi S Cureus; 2023 Sep; 15(9):e44888. PubMed ID: 37814744 [TBL] [Abstract][Full Text] [Related]
51. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico. Peña Rodríguez M; Hernández Bello J; Vega Magaña N; Viera Segura O; García Chagollán M; Ceja Gálvez HR; Mora Mora JC; Rentería Flores FI; García González OP; Muñoz Valle JF Front Public Health; 2023; 11():1149795. PubMed ID: 37181688 [TBL] [Abstract][Full Text] [Related]
52. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857 [TBL] [Abstract][Full Text] [Related]
53. Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection. Sočan M; Mrzel M; Prosenc K; Korva M; Avšič-Županc T; Poljak M; Lunar MM; Zupanič T Front Public Health; 2024; 12():1294261. PubMed ID: 38450129 [TBL] [Abstract][Full Text] [Related]
54. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study. Nakakubo S; Kishida N; Okuda K; Kamada K; Iwama M; Suzuki M; Yokota I; Ito YM; Nasuhara Y; Boucher RC; Konno S Lancet Infect Dis; 2023 Nov; 23(11):1244-1256. PubMed ID: 37399831 [TBL] [Abstract][Full Text] [Related]
55. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296 [TBL] [Abstract][Full Text] [Related]
57. Prevalence and risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong. Luo J; Zhang J; Tang HT; Wong HK; Lyu A; Cheung CH; Bian Z J Med Virol; 2023 Jun; 95(6):e28862. PubMed ID: 37334978 [TBL] [Abstract][Full Text] [Related]
58. Association between virus variants, vaccination, previous infections, and post-COVID-19 risk. Diexer S; Klee B; Gottschick C; Xu C; Broda A; Purschke O; Binder M; Frese T; Girndt M; Hoell JI; Moor I; Gekle M; Mikolajczyk R Int J Infect Dis; 2023 Nov; 136():14-21. PubMed ID: 37634619 [TBL] [Abstract][Full Text] [Related]
59. COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants. Hernández-Aceituno A; García-Hernández A; Larumbe-Zabala E Infect Dis Now; 2023 Aug; 53(5):104688. PubMed ID: 36858287 [TBL] [Abstract][Full Text] [Related]
60. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. Magnusson K; Kristoffersen DT; Dell'Isola A; Kiadaliri A; Turkiewicz A; Runhaar J; Bierma-Zeinstra S; Englund M; Magnus PM; Kinge JM Nat Commun; 2022 Nov; 13(1):7363. PubMed ID: 36450749 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]